• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

TRANSFORM Trial Unveiled: AI-Powered Approach for Personalized Heart Disease Care

by Jasmine Pennic 11/21/2023 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Cleerly, a leading innovator in the field of cardiovascular disease diagnosis, today announced the launch of the TRANSFORM trial at the American Heart Association’s (AHA) 2023 Scientific Sessions. This groundbreaking trial aims to revolutionize the way heart disease is prevented by evaluating a personalized care strategy based on Cleerly’s AI-powered coronary artery disease (CAD) plaque staging system.

About the TRANSFORM Trial

The TRANSFORM trial is a randomized, controlled trial that will enroll 7,500 patients with pre-diabetes, type 2 diabetes, or metabolic syndrome who have no symptoms of heart disease. Participants will be randomly assigned to either a personalized care strategy or to usual care, and all participants will undergo a coronary computed tomography angiography (CCTA) scan.

Personalized Care Strategy

Patients in the personalized care arm will receive a detailed CAD plaque staging report based on their CCTA scan. This report will provide their healthcare provider with a comprehensive assessment of their coronary artery plaque burden, which is a major risk factor for heart attacks. The healthcare provider will then use this information to develop a personalized treatment plan that may include lifestyle changes, medication, or both.

Usual Care

Patients in the usual care arm will be treated based on traditional cardiovascular risk factors, such as age, blood pressure, cholesterol levels, and smoking status. They will not receive a CAD plaque staging report.

End Goal: Preventing Heart Attacks

The primary goal of the TRANSFORM trial is to determine whether a personalized care strategy based on Cleerly’s CAD plaque staging system is more effective than usual care at preventing cardiovascular events, such as heart attacks and strokes.

Partnerships

Cleerly is partnering with several leading organizations on the TRANSFORM trial, including:

  • AGEPHA Pharma
  • CPC Clinical Research
  • Esperion Therapeutics
  • Heartbeat Health
  • Lexicon Pharmaceuticals
  • American Heart Association

Leadership

The TRANSFORM trial is being led by a team of renowned cardiologists, including:

  • Deepak L. Bhatt, MD, MPH, FACC, FAHA, FESC, MSCAI, Director of Mount Sinai Fuster Heart Hospital; Dr. Valentin Fuster Professor of Cardiovascular Medicine, Icahn School of Medicine at Mount Sinai
  • David Maron, MD, C.F. Rehnborg Professor and Professor of Medicine; Director, Stanford Prevention Research Center, Stanford University School of Medicine
  • Marc Bonaca, MD, MPH, FAHA, FACC, Executive Director of CPC Clinical Research; William R. Hiatt Endowed Chair in Cardiovascular Research; Professor of Medicine, Cardiology & Vascular Medicine and Director of Vascular Research, University of Colorado School of Medicine

Significance of the TRANSFORM Trial

The TRANSFORM trial is a pivotal study that has the potential to transform the way heart disease is prevented. By identifying patients at high risk of heart attacks based on their individual coronary artery plaque burden, healthcare providers can develop personalized treatment plans that can help to prevent these events.

Next Steps

TRANSFORM trial recruitment is scheduled to close in late 2025, and results can be expected in late 2028. For more information, please visit transformtrial.org.

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Artificial Intelligence, Clinical Trials

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Paradigm Shift in Diabetes Care with Studio Clinics: Q&A with Reach7 Founder Chun Yong

Most-Read

Omada Health Launches "Nutritional Intelligence" with AI Agent OmadaSpark

Omada Health Soars in NASDAQ Debut, Signaling Digital Health IPO Rebound

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |